The clinical course of multiple sclerosis patients in Hong Kong

被引:26
作者
Lau, Kwok-Kwong [1 ]
Wong, Winnie Wing-Yin [2 ]
Sheng, Bun [1 ]
Yu, Ignatius Tak-Sun [3 ]
Fung, Bun-Hey [4 ]
Li, Ho-Lun [1 ]
Ma, Ka-Fai Johnny [5 ]
Wong, Lawrence Ka-Sing [6 ]
Li, Patrick Chung-Ki [2 ]
机构
[1] Princess Margaret Hosp, Dept Med & Geriatr, Kwai Chung, Hong Kong, Peoples R China
[2] Queen Elizabeth Hosp, Dept Med & Geriatr, Kowloon, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, Dept Community & Family Med, Shatin, Hong Kong, Peoples R China
[4] United Christian Hosp, Dept Med & Geriatr, Kwun Tong, Hong Kong, Peoples R China
[5] Princess Margaret Hosp, Dept Radiol, Kwai Chung, Hong Kong, Peoples R China
[6] Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
关键词
multiple sclerosis; epidemiology; disease progression; Extended Disability Status Scale;
D O I
10.1016/j.jns.2007.11.006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis (MS) has a low prevalence in Hong Kong. Objective: To reassess MS prevalence in Hong Kong and to examine associated risk factors for relapsing-remitting type MS patients to reach Kurtzke's Extended Disability Status Scale (EDSS) of 6.0, i.e. when walking aid was needed. Design: Retrospective observational study on MS patients over 11 years. Setting: Three tertiary hospitals in Hong Kong. Results: A hundred and six patients were recruited. Female to male ratio was 3.2:1 and the prevalence was 4.8 per 100,000.95 were relapsing-remitting (RR) type. The mean disease duration was 12.7 years (range: 1-45 years) and the duration of follow up was 11.0+/-0.8 (mean+/-SE) years. The initial mean EDSS was 1.59 and the latest mean EDSS was 4.26. 38 (40%) RR type MS patients progressed to EDSS 6.0 after a mean duration of 6.0 years. With Cox regression analysis, patients with older age (>35y) of onset (HR 2.57; 95% CI:1.29-5.11), higher EDSS of 2.0 or more upon presentation (HR 2.19; 95%CI: 1.12-4.26) were associated with progression to EDSS of 6.0, while there was a tendency towards slower disease progression for patients initially presenting with optic symptoms (HR 0.52; 95%CI: 0.23-1.16). The number of relapses and use of interferon could not be shown to have significant effect on disease progression. Conclusions: The local period prevalence ratio of MS was 4.8 per 100,000. Older age of onset and higher EDSS upon initial presentation were independent predictors for progression to EDSS of 6.0. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:78 / 82
页数:5
相关论文
共 27 条
  • [1] Relapses and progression of disability in multiple sclerosis.
    Confavreux, C
    Vukusic, S
    Moreau, T
    Adeleine, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (20) : 1430 - 1438
  • [2] Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process
    Confavreux, C
    Vukusic, S
    Adeleine, P
    [J]. BRAIN, 2003, 126 : 770 - 782
  • [3] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DUQUETTE, P
    GIRARD, M
    DESPAULT, L
    DUBOIS, R
    KNOBLER, RL
    LUBLIN, FD
    KELLEY, L
    FRANCIS, GS
    LAPIERRE, Y
    ANTEL, J
    FREEDMAN, M
    HUM, S
    GREENSTEIN, JI
    MISHRA, B
    MULDOON, J
    WHITAKER, JN
    EVANS, BK
    LAYTON, B
    SIBLEY, WA
    LAGUNA, J
    KRIKAWA, J
    PATY, DW
    OGER, JJ
    KASTRUKOFF, LF
    MOORE, GRW
    HASHIMOTO, SA
    MORRISON, W
    NELSON, J
    GOODIN, DS
    MASSA, SM
    GUTTERIDGE, E
    ARNASON, BGW
    NORONHA, A
    REDER, AT
    MARTIA, R
    EBERS, GC
    RICE, GPA
    LESAUX, J
    JOHNSON, KP
    PANITCH, HS
    BEVER, CT
    CONWAY, K
    WALLENBERG, JC
    BEDELL, L
    VANDENNOORT, S
    WEINSHENKER, B
    WEISS, W
    REINGOLD, S
    PACHNER, A
    TAYLOR, W
    [J]. NEUROLOGY, 1993, 43 (04) : 655 - 661
  • [4] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
    Ebers, GC
    Rice, G
    Lesaux, J
    Paty, D
    Oger, J
    Li, DKB
    Beall, S
    Devonshire, V
    Hashimoto, S
    Hooge, J
    Kastrukoff, L
    Krieger, C
    Mezei, M
    Seland, P
    Vorobeychi, G
    Morrison, W
    Nelson, J
    Freedman, MS
    Chrisie, S
    Nelson, R
    Rabinovitch, H
    Freedman, C
    Hartung, HP
    Rieckmann, P
    Archelos, J
    Jung, S
    Weilbach, F
    Flachenecke, P
    Sauer, J
    Hommes, O
    Jongen, P
    Brouwer, S
    McLeod, J
    Pollard, J
    Ng, R
    Sandberg-Wollheim, M
    Källén, K
    Nilsson, P
    Ekberg, R
    Lundgren, A
    Jadbäck, G
    Wikström, J
    Multanen, J
    Valjakka, M
    Carton, H
    Lissoir, F
    Declerq, I
    Vieren, M
    Peeters, E
    Dubois, B
    [J]. LANCET, 1998, 352 (9139) : 1498 - 1504
  • [5] UNSUSPECTED MULTIPLE-SCLEROSIS
    GILBERT, JJ
    SADLER, M
    [J]. ARCHIVES OF NEUROLOGY, 1983, 40 (09) : 533 - 536
  • [6] Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors
    Hawkins, SA
    McDonnell, GV
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (02) : 148 - 152
  • [7] HEMDON RM, 1983, ARCH NEUROL-CHICAGO, V40, P531
  • [8] Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis:: a 3-year follow-up analysis of the BENEFIT study
    Kappos, Ludwig
    Freedman, Mark S.
    Polman, Chris H.
    Edan, Gilles
    Hartung, Hans-Peter
    Miller, David H.
    Montalban, Xavier
    Barkhof, Frederik
    Radu, Ernst-Wilheim
    Bauer, Lars
    Dahms, Susanne
    Lanius, Vivian
    Pohl, Christoph
    Sandbrink, Rupert
    [J]. LANCET, 2007, 370 (9585) : 389 - 397
  • [9] Kira J, 1996, ANN NEUROL, V40, P569
  • [10] STUDIES ON NATURAL-HISTORY OF MULTIPLE-SCLEROSIS .8. EARLY PROGNOSTIC FEATURES OF LATER COURSE OF ILLNESS
    KURTZKE, JF
    BEEBE, GW
    NAGLER, B
    KURLAND, LT
    AUTH, TL
    [J]. JOURNAL OF CHRONIC DISEASES, 1977, 30 (12): : 819 - 830